Close Menu

NEW YORK (GenomeWeb) – Exact Sciences today reported preliminary fourth quarter revenue of $14 million to $14.5 million, slightly below analyst estimates of $15.9 million. The company also said it expects full-year 2015 revenues of $39 million to $39.5 million.

Exact said it completed 38,000 Cologuard tests during Q4, and about 104,000 tests during the year — 2015 was the first full year of commercialization for the non-invasive colorectal cancer screening test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.